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HGT, has contributed to advancing the understanding and man-
agement of Fabry disease—a rare lysosomal storage disorder
caused by deﬁciency of the enzyme a-galactosidase A.
METHODS: FOS—a prospective database that collects informa-
tion on demographics, signs and symptoms, investigations and
patient-reported outcomes for patients with a conﬁrmed diagno-
sis of Fabry disease—was established in 2001. Working groups
were appointed to analyse, interpret and publish data to further
the understanding of the natural history of the disease and the
response to enzyme replacement therapy with agalsidase alfa.
RESULTS: As of May 2008, 19 countries have enrolled 1528
patients (799 females, 729 males). Of these, 138 are girls and 123
boys less than 18 years of age. Signiﬁcant peer-reviewed pub-
lished ﬁndings include evidence of the range and progression of
signs and symptoms in males and females (Mehta et al., 2004;
Deegan et al., 2006), which have shown that affected women are
not simply ‘carriers’ of the disease, but may experience a wide
range of symptoms. FOS has also demonstrated that boys and
girls may experience symptoms from an early age (Ramaswami
et al., 2006). Evidence on the effectiveness of agalsidase alfa (2
years of treatment) on various signs and symptoms such as renal
function (Schwarting et al., 2006), pain (Hoffmann et al., 2007a)
and gastrointestinal symptoms (Hoffmann et al., 2007b) has also
been reported. CONCLUSIONS: FOS has provided an impor-
tant evidence base that has helped to advance the management of
Fabry disease in males and females across all ages. Evidence on
the onset and progression of the disease in females and children
has been especially important to help achieve an early diagnosis,
support clinical decision making and guide management to help
optimize patient care.
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OBJECTIVES: The study was performed to estimate the preva-
lence of obesity and associated risk factors such as type 2 dia-
betes or dyslipidaemia in the Korean adult population.
METHODS: The third Korean National Health and Nutrition
Examination Survey in 2005 (KNHANES III) data was used. For
the estimation of prevalence of overall obesity (deﬁned by body
mass index, BMI) in this report, subjects were selected as adults
over 18 years old and completed health examinations. Each
sampling weights was used for the analysis. Weights were given
as an inverse of the probability of selection, and a non-response
adjustment weight. Prevalence of obesity was calculated as the
weighted number of obese people divided by the weighted
number of all eligible people. Numbers of people with obesity
and related metabolic abnormalities were estimated with multi-
plying the calculated prevalence by the total Korean population.
RESULTS: Among the Korean adult population (age 18 years
or more), proportions of people with BMI  25.0 kg/m2,
27.0 kg/m2 and 30.0 kg/m2 were estimated to 28.1%, 13.2%
and 3.2%, respectively. Within the group BMI  27.0 kg/m2,
9.1% had type 2 diabetes. Among them, 64.6% were diagnosed
for T2DM and 21.5% of the diagnosed were untreated. In the
same group, the people who had any HDL/TG abnormality
without T2DM were 49.4% and only 8.2% of them were pre-
viously diagnosed by physician. Overall 70% of the people with
BMI 27.0 kg/m2 or higher had at least one metabolic abnorma-
lity like T2DM, HDL/TG abnormality, pre-diabetes or high
serum LDL-C. CONCLUSIONS: This study showed the current
situation of obesity and related metabolic abnormalities among
Korean population based on KNHANES III data. It will be a
good reference for the development of national strategy to
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OBJECTIVES: Immune thrombocytopenic purpura (ITP) is a
rare and life-threatening autoimmune disorder characterized by
increased destruction and impaired production of blood plate-
lets by auto-antibodies. International epidemiological studies
reported yearly incidence and prevalence of respectively 2 and
10 cases/100,000 persons. No Belgian epidemiological data are
currently available. To estimate the incidence and prevalence
of adult chronic ITP in Belgium using hospital records.
METHODS: The incidence of adult chronic ITP was estimated
using the National statistics on Diagnosis Related Group for
splenectomy (DRG 650, year 2004). The prevalence was esti-
mated using the longitudinal IMS Hospital Disease Database
(year 2006), including data of 34.3% of Belgian hospitals. All
admissions to hospital with a diagnosis of Primary Thromb-
ocytopenia (ICD-9-CM 287.3) were retrieved for patients aged
>20 years. The repartition of cases by age and sex was inves-
tigated. RESULTS: A total of 229 splenectomies were per-
formed in adults in 2004. Assuming that 10–30% of
splenectomies are ITP-related and 20–40% of chronic ITP
patients are splenectomized, this results in a yearly incidence of
0.7–4.3 new ITP cases per 100,000 adults, i.e. 57–344 new
cases/year. In 2006, 657 admissions for primary thrombocy-
topenia were recorded in the Hospital Disease database, for
350 distinct adult patients. This corresponds to an estimated
prevalence of 12.6 per 100,000 adults per annum, i.e. 1020
patients. A quadratic increase of the prevalence was observed
with age: from 5.8 to 39.8 cases per 100,000 per year in the
age groups of 20–29 years to 75 years. The prevalence was
2.7 times higher in women aged 20–55 years vs. men
(p < 0.001), but similar in patients aged older. CONCLU-
SIONS: Although non-hospitalized patients were not captured
in this analysis, these Belgian incidence and prevalence data are
consistent with published international data. The prevalence of
ITP increases substantially with age. Prevalence is also higher in
women in younger age groups.
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OBJECTIVES: To determine the correlations between diseases,
patients, drugs factors and systemic lupus erythematosus (SLE)
disease activity. To establish model for predicting SLE disease
activity. METHODS: The Cross-sectional survey method was
applied, SLE patients who visit rheumatologist at Nopparat
Rajathanee hospital were interviewed during November 1, 2007
to February 29, 2008, disease duration, infection, SLE knowl-
edge, self management, stress and compliance were collected and
evaluated to ﬁnd correlation with disease activity scores (measure
by MEX-SLEDAI). Multiple Regression Analysis was applied to
identify model for predict the disease activity. RESULTS: Data
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from 132 SLE patients were analyzed. The infection was found
in 30 SLE patients. The mean disease activity score in infected
group was higher than the score in non-infected group.
(p < 0.001) Stress and non-compliance were signiﬁcant positively
associated with more disease activity (r = +0.242, r = +0.276,
p = 0.005, 0.001 respectively). Disease duration, SLE knowledge
and self-management were non-statistically signiﬁcant with
disease activity. Infection, stress and compliance were predicted
factors in disease activity model. CONCLUSIONS: Factors asso-
ciated with SLE disease activity were infection, stress and
non-compliance.
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OBJECTIVES: To contrast the factors that are associated with
metabolic syndrome risk for US adolescents overall and US His-
panic adolescents. METHODS: At risk is deﬁned as having three
or more of the following: elevated fasting glucose, elevated SBP,
elevated DBP, elevated triglycerides, elevated BMI, elevated waist
circumference, or low HDL. Logistic regression and NHANES
2003–2006 data were used to examine the impact on metabolic
syndrome risks; gender, race, ethnicity, immigrant status, income,
insurance, parental education, activity levels, number of school
lunches and breakfasts per week, milk consumption, language
preference, and number of meals outside the home per week. US
adolescents overall were compared with US Hispanic adoles-
cents. Weighted sample sizes for Hispanic adolescents and US
born adolescents were 8,178,714, and 50,837,204 respectively.
At risk is deﬁned as having three or more of the following:
elevated fasting glucose, elevated SBP, elevated DBP, elevated
triglycerides, elevated BMI, elevated waist circumference, or low
HDL. Logistic regression and NHANES 2003–2006 data were
used to examine the impact on metabolic syndrome risks; gender,
race, ethnicity, immigrant status, income, insurance, parental
education, activity levels, number of school lunches and break-
fasts per week, milk consumption, language preference, and
number of meals outside the home per week. US adolescents
overall were compared with US Hispanic adolescents. Weighted
sample sizes for Hispanic adolescents and US born adolescents
were 8,178,714, and 50,837,204 respectively. RESULTS: The
results of the regressions were vastly different between US ado-
lescents and US Hispanic (First Generation and Native) adoles-
cents. All variables in the models were statistically signiﬁcant.
Where US adolescent females faced a lower risk (42%) of having
metabolic syndrome, US Hispanic females faced a higher risk
(17%). Notably, for those Hispanics that were ﬁrst generation,
risk increased by 65%. For US adolescents overall, low or middle
income levels increased risk three times, while low and middle
income level US Hispanic adolescents had a risk decrease of 77%
and 69% respectively. For every meal eaten outside the home per
week (excluding school meals) metabolic syndrome risk increases
for US adolescents by 4% and by 13% for Hispanic US adoles-
cents. CONCLUSIONS: Adolescents with metabolic syndrome
are at risk for acute cardiovascular endpoints, higher medical
utilization and expenditure, and lower quality of life. Interven-
tions should focus on education regarding healthy eating outside
the home despite limited ﬁnancial resources. A surprising result
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OBJECTIVES: To examine the 5-year economic consequences
of reimbursing laparoscopic adjustable gastric banding (LAGB)
in addition to laparoscopic gastric bypass (LGBY) for a large
US managed care organization. METHODS: We used a Markov
model to estimate surgical costs and outcomes, weight loss, and
obesity-related costs and outcomes for LAGB, LGBY and no
treatment over a 5-year period for a hypothetical 1-million-
member managed care plan. Weight loss was estimated from a
randomized clinical trial (LAGB causes somewhat less weight
loss than LGBY). Complication rates, treatment and adverse
event costs, and medical costs were estimated from published and
publicly-available sources (LAGB has less severe complications
than LGBY). The treatment-eligible population was estimated
from US obesity rates, treatment guidelines, and clinical experi-
ence. Market expansion and substitution between LAGB and
LGBY were projected from historical trends and physician/
patient surveys. Budgetary impact, measured in 2007 dollars,
was calculated as net cost with LAGB versus without LAGB;
deterministic sensitivity analyses identiﬁed model drivers.
RESULTS: Mean 5-year cost for LAGB was less than LGBY at
$41,800 versus $52,800 per surgically-treated patient, primarily
due to lower surgical and complication costs. The net budgetary
impact was 14.5 M over 5 years ($1.8 M in year 1, rising to
$3.6 M in year 5). Net 5-year costs associated with market
expansion totaled $47.9 M, while patients receiving LAGB
instead of LGBY saw net cost-savings totaling $33.4 M. Results
are sensitive to estimates of the proportion of patients that would
choose LGBY in the absence of the LAGB option (net budgetary
impact: +$32.8 M to -$5.2 M) and estimates of market expan-
sion (net budgetary impact: $12.3 M to $16.6 M). CONCLU-
SIONS: For a hypothetical 1-million-member managed-care
organization, the estimated 5-year budgetary impact of reimburs-
ing LAGB is approximately $14.5 M. Although plan expendi-
tures increase as additional patients seek surgical treatment,
substantial savings are realized for patients receiving LAGB
instead of LGBY.
PSY8
BUDGET IMPACT ANALYSIS OF DEFERASIROX FORTHE
TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS
WITH BETATHALASSAEMIA INVENETO REGION, ITALY
Venturini F,Adami S,Alberti C, Scroccaro G
Veneto Regional Drug Information Center,Verona, Italy
OBJECTIVES: This study aims to estimate the budget impact of
deferasirox (a once-daily oral iron chelator recently marketed in
Italy) in patients with beta-thalassaemia major and chronic iron
overload from blood transfusions, who live in the Veneto region.
Our analysis compares the costs of deferasirox versus deferox-
amine (which is the current standard of care for these patients)
and versus deferiprone, another oral iron chelator that is
licensed only for the treatment of iron-overloaded thalassaemic
patients, when deferoxamine is contraindicated or inadequate.
METHODS: Our analyses was conducted from the perspective
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